Researchers report early trial results for rentosertib, an AI-discovered drug originally developed to treat idiopathic pulmonary fibrosis (IPF), a progressive lung scarring disease. In a Phase 2a study, the drug is tested on 42 patients over 12 weeks.
Both outlets describe findings that suggest a potential “aging” effect measured through biological markers. Fox News reports that participants appeared about three to four years biologically younger after treatment, framing this as a surprising “bonus” beyond the drug’s intended purpose. NDTV similarly highlights that the drug shows early signs of slowing aging, without adding further outcome details in the provided excerpt.
While the reports agree on the drug, its origin in IPF research, the Phase 2a design, and the early nature of the results, they differ in emphasis—Fox focuses on the estimated magnitude of biological age reduction, while NDTV focuses on the study context and early signs of slowed aging.
